Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.

Some neonates with Down syndrome (DS) are diagnosed with self-regressing transient myeloproliferative disorder (TMD), and 20% to 30% of those progress to acute megakaryoblastic leukemia (AMKL). We performed exome sequencing in 7 TMD/AMKL cases and copy-number analysis in these and 10 additional cases. All TMD/AMKL samples contained GATA1 mutations. No exome-sequenced TMD/AMKL sample had other recurrently mutated genes. However, 2 of 5 TMD cases, and all AMKL cases, showed mutations/deletions other than GATA1, in genes proven as transformation drivers in non-DS leukemia (EZH2, APC, FLT3, JAK1, PARK2-PACRG, EXT1, DLEC1, and SMC3). One patient at the TMD stage revealed 2 clonal expansions with different GATA1 mutations, of which 1 clone had an additional driver mutation. Interestingly, it was the other clone that gave rise to AMKL after accumulating mutations in 7 other genes. Data suggest that GATA1 mutations alone are sufficient for clonal expansions, and additional driver mutations at the TMD stage do not necessarily predict AMKL progression. Later in infancy, leukemic progression requires "third-hit driver" mutations/somatic copy-number alterations found in non-DS leukemias. Putative driver mutations affecting WNT (wingless-related integration site), JAK-STAT (Janus kinase/signal transducer and activator of transcription), or MAPK/PI3K (mitogen-activated kinase/phosphatidylinositol-3 kinase) pathways were found in all cases, aberrant activation of which converges on overexpression of MYC.

[1]  J. Crispino,et al.  AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL , 2013, Leukemia.

[2]  S. Antonarakis,et al.  A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. , 2012, Cancer research.

[3]  Julia C. Engelmann,et al.  Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. , 2012, Blood.

[4]  Q. Tao,et al.  Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas , 2012, Journal of Translational Medicine.

[5]  D. Nižetić,et al.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome , 2012, Nature Reviews Cancer.

[6]  R. Pieters,et al.  High frequency of copy number alterations in myeloid leukaemia of Down syndrome , 2012, British journal of haematology.

[7]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[8]  H. Hock.  A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.

[9]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[10]  C. V. Jongeneel,et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.

[11]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[12]  P. Guglielmelli,et al.  EZH2 mutational status predicts poor survival in myelofibrosis. , 2011, Blood.

[13]  Charles P. Lin,et al.  Differential niche and Wnt requirements during acute myeloid leukemia progression. , 2011, Blood.

[14]  A. Fatica,et al.  Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. , 2011, Genes & cancer.

[15]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[16]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[17]  T. Lister,et al.  Heterogeneous sensitivity of human Acute Myeloid Leukemia to ß-catenin down-modulation , 2011, Leukemia.

[18]  A. McKenzie,et al.  Advances in the 5q- syndrome. , 2010, Blood.

[19]  B. Nadel,et al.  Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. , 2010, Blood.

[20]  S. Orkin,et al.  Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. , 2010, Genes & development.

[21]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[22]  M. L. Le Beau,et al.  Haploinsufficiency of Apc leads to ineffective hematopoiesis. , 2010, Blood.

[23]  Ola Larsson,et al.  The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[24]  Henriette O'Geen,et al.  Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. , 2009, Molecular cell.

[25]  Brent L Wood,et al.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. , 2009, Blood.

[26]  J. Downing,et al.  Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia , 2009, Proceedings of the National Academy of Sciences.

[27]  S. Izraeli,et al.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. , 2009, Blood.

[28]  D. Nižetić,et al.  Megakaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalis , 2008, British journal of haematology.

[29]  R. Wilson,et al.  Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. , 2008, Blood.

[30]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[31]  P. Vyas,et al.  Haematology of Down syndrome , 2007, Archives of Disease in Childhood Fetal and Neonatal Edition.

[32]  P. Vyas,et al.  Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. , 2007, Blood.

[33]  S. Raimondi,et al.  Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia , 2007, Genes, chromosomes & cancer.

[34]  D. Nižetić,et al.  Loss‐of‐function JAK3 mutations in TMD and AMKL of Down syndrome , 2007, British journal of haematology.

[35]  Kyu-Tae Kim,et al.  FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells , 2007, British journal of haematology.

[36]  P. Vyas,et al.  Molecular insights into Down syndrome-associated leukemia , 2007, Current opinion in pediatrics.

[37]  G. Ghiselli.  SMC3 knockdown triggers genomic instability and p53-dependent apoptosis in human and zebrafish cells , 2006, Molecular Cancer.

[38]  R. Braziel,et al.  FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248) , 2006, Leukemia.

[39]  J. Minna,et al.  Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia , 2006, International journal of cancer.

[40]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Bernards,et al.  The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling , 2005, Cell.

[42]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[43]  M. Asashima,et al.  Maternal Wnt11 Activates the Canonical Wnt Signaling Pathway Required for Axis Formation in Xenopus Embryos , 2005, Cell.

[44]  Manel Esteller,et al.  Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. , 2004, Human molecular genetics.

[45]  D. Nižetić,et al.  Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker , 2004, British journal of haematology.

[46]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[47]  L. Chodosh,et al.  GATA-1-Mediated Proliferation Arrest during Erythroid Maturation , 2003, Molecular and Cellular Biology.

[48]  D. Nižetić,et al.  Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder , 2003, The Lancet.

[49]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[50]  A. Zipursky,et al.  Incidence and Treatment of Potentially Lethal Diseases in Transient Leukemia of Down Syndrome: Pediatric Oncology Group Study , 2002, Journal of pediatric hematology/oncology.

[51]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[52]  E. Schröck,et al.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.

[53]  A. Zipursky,et al.  Leukemia in Down syndrome: a review. , 1992, Pediatric hematology and oncology.

[54]  R. Good,et al.  Simultaneous occurrence of mongolism and leukemia; report of a nationwide survey. , 1957, A.M.A. journal of diseases of children.